AbbVie and Genmab's epcoritamab plus R-CHOP reduced the risk of disease progression or death by 51% versus R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma, the first Phase 3 win for a bispecific combination in the frontline setting.
October 6, 2026Vaxcyte's 31-valent pneumococcal conjugate vaccine met all primary immunogenicity endpoints in the OPUS-1 Phase 3 trial, positioning it to challenge Pfizer's Prevnar 20 and Merck's Capvaxive. Shares closed up 31%.
October 6, 2026ArriVent's firmonertinib missed the Phase 3 FURVENT primary endpoint in first-line EGFR exon 20 NSCLC, sending shares down 47% to $15.09.
October 6, 2026 · oncology · $AVBPAstraZeneca is making a $2 billion equity investment in Summit Therapeutics and teaming up to test ivonescimab with its ADC portfolio, a major validation of the PD-1/VEGF bispecific ahead of its November PDUFA.
September 29, 2026The FDA accepted Alexion's BLA for efzimfotase alfa and granted Priority Review for hypophosphatasia in patients 2 and older. A decision is expected in H1 2027.
September 29, 2026Adicet Bio reported that 54% of patients in its Phase 1 lupus study met DORIS remission at 12 months, a first durability print for an allogeneic CAR-T.
September 28, 2026Both Zenkuda and KSI-501 met non-inferiority versus aflibercept in the DAYBREAK Phase 3 wet AMD trial, with 54% of Zenkuda patients on a 24-week dosing interval.
September 28, 2026 · Ophthalmology · $KODMirum's brelovitug hit the AZURE-1 primary endpoint in chronic hepatitis delta, with 56% of the weekly-dose arm achieving virologic response plus ALT normalization versus 0% on delayed treatment.
September 28, 2026 · Rare disease · $MIRMMerck licensed preclinical oral KRAS G12D(ON) inhibitor SPR2015 from China-based SciBrunch for $400 million upfront, in a deal worth up to $2.13 billion.
September 28, 2026FDA accepted Pharming's sNDA for lower-dose Joenja (leniolisib) in children 4+ weighing 13-27 kg with APDS, granting Priority Review. PDUFA is Jan 30, 2027.
September 28, 2026FDA approved Roche's Gazyva (obinutuzumab) to cut relapse risk for ages 2+ with frequently relapsing nephrotic syndrome. INSHORE hit 95.5% vs 73.2% remission.
September 28, 2026SCYNEXIS (SCYX) won a BARDA contract worth up to $214M to advance antifungal SCY-247 through NDA submission. The committed base period is just $18.5M.
September 28, 2026AbbVie's Qulipta cut menstrual migraine days by 0.80 versus placebo in Phase 3 LUNA, the first CGRP-targeted drug to win specifically in this indication.
September 27, 2026Alexion's Klygefa, a once-weekly subcutaneous C5 inhibitor, won a CHMP recommendation for generalized myasthenia gravis. An EU decision follows in two months.
September 27, 2026Immunovant ends IMVT-1402 in cutaneous lupus after the Phase 2 trial missed its CLASI-A endpoint at Week 12. Deeper IgG cuts still predicted response.
September 27, 2026The FDA accepted Nanoscope's BLA for MOGENRY, an optogenetic gene therapy for retinitis pigmentosa that bypasses the mutated gene. No decision date is set.
September 27, 2026Novo Nordisk's once-weekly Wegovy moved 40.4% of children aged 6 to 11 below the obesity threshold versus 0% on placebo in the Phase 3 STEP Young trial.
September 27, 2026Xenon filed its first NDA for azetukalner, a KV7 potassium channel opener for focal seizures, then paused psychiatry enrollment on a neuropsychiatric signal.
September 27, 2026Bristol Myers presented full Phase 3 EXCALIBER-RRMM data at IMS 2026: Zenbexus doubled the MRD-negative CR rate (41.1% vs 20.7%), but PFS is still pending.
September 26, 2026The FDA accepted Cogent's bezuclastinib NDA for advanced systemic mastocytosis, setting a June 29, 2027 PDUFA date as its third shot on goal for the drug.
September 26, 2026CARVYKTI kept half of CARTITUDE-2 patients progression-free five years after one infusion. Median PFS hit 60.5 months and overall survival was not reached.
September 26, 2026The FDA approved Lilly's Olumiant for severe alopecia areata in patients 12 and up, the second oral JAK inhibitor for adolescents behind Pfizer's LITFULO.
September 26, 2026Lisata is reverse-merging with Marea and raising a $225M PIPE to advance MAR001, an anti-ANGPTL4 antibody in Phase 2b for severe hypertriglyceridemia.
September 26, 2026Novo will pay Nanexa up to $1.33B for its PharmaShell platform to develop monthly and quarterly GLP-1 injections. The $700M upfront is real near-term cash.
September 26, 2026REGENXBIO's sura-vec showed 60% of patients hit a two-step DRSS improvement at three years in diabetic retinopathy, extending its one-time gene therapy thesis.
September 26, 2026The FDA accepted Takeda's zasocitinib NDA under Priority Review for plaque psoriasis. The once-daily oral TYK2 inhibitor challenges BMS's Sotyktu in 2027.
September 26, 2026Telix agreed to buy ITM for $1.65B upfront, up to $2.35B total, the largest radiopharma deal yet, adding the key 177Lu isotope supplier to its pipeline.
September 26, 2026FDA approves AbbVie's Juvmo (tavapadon) for Parkinson's, the first selective D1/D5 partial agonist to reach market. ABBV barely moved: it was priced in.
September 25, 2026 · Neuroscience · $ABBVThe San Diego siRNA biotech raised $446.3M at $17 per share, the top of its $15-$17 range, with AbbVie buying a ~4.9% stake in a concurrent $100M placement. Total gross proceeds: ~$535.2M.
September 25, 2026 · RNAi / siRNA therapeutics · $ADRXArcturus reported safe, biomarker-improving Phase 2 data for ARCT-810 in OTC deficiency and unveiled LUNAR 2.0, plus a deal to acquire the AI firm myNEO.
September 25, 2026AstraZeneca's Etcamah missed the SERENA-4 first-line breast cancer endpoint, capping the oral SERD to the ESR1-mutant niche. Its accelerated approval is intact.
September 25, 2026FDA granted Priority Review to AstraZeneca's Imfinzi plus enfortumab vedotin for cisplatin-ineligible bladder cancer. A decision is expected in Q4 2026.
September 25, 2026Gossamer Bio filed its first NDA for seralutinib in PAH after a 1-for-80 reverse split. If the FDA accepts the filing, a decision could come in Q3 2027.
September 25, 2026The CHMP recommended Incyte's Povofortay (povorcitinib), setting up the JAK1 inhibitor to become the first daily oral pill for hidradenitis suppurativa.
September 25, 2026Ionis and Otsuka's ulefnersen met its primary endpoint in the Phase 3 FUSION trial in FUS-ALS (p=0.0005), the first placebo-controlled win for a therapy targeting the disease's genetic cause.
September 25, 2026 · Neurology · $IONSJ&J said Tremfya hit its endpoints in the Phase 4 STAR study in axial psoriatic arthritis, the first IL-23 to show a spinal pain benefit in a dedicated trial.
September 25, 2026The FDA granted full approval to Lilly's Inluriyo plus Verzenio for ESR1-mutant metastatic breast cancer. The combo doubled PFS to 11.1 months versus 5.5.
September 25, 2026The FDA approved Mirum's Atebrioz (zilurgisertib) for FOP in patients 12 and older, the third drug and first ALK2 inhibitor for the disease, cutting new bone volume 3.2 cm3 versus a 24.6 cm3 increase on placebo.
September 25, 2026 · Rare Disease · $MIRMMerck and Daiichi Sankyo withdrew the ifinatamab deruxtecan SCLC BLA after the FDA said Phase 2 data do not support accelerated approval. Oct 10 PDUFA is off.
September 25, 2026 · Oncology · $MRKFDA cleared belzutifan plus lenvatinib for advanced clear-cell renal cell carcinoma after PD-1/PD-L1 therapy on Sept 24, 2026, 10 days ahead of the Oct 4 PDUFA date.
September 25, 2026 · oncology · $MRKThe CHMP recommended EU approval of Novo Nordisk's Frehemgo (denecimig) for hemophilia A, even as the drug's July 29 US PDUFA decision stays unresolved.
September 25, 2026The FDA approved Telix's Pixclara (floretyrosine F 18), the first amino-acid PET imaging tracer to tell recurrent glioma apart from treatment-related change.
September 25, 2026Barzolvolimab met the primary and all key secondary endpoints in EMBARQ-CSU1 and CSU2 in chronic hives, but two anaphylaxis cases sent Celldex shares down about 12%.
September 24, 2026 · immunology · $CLDXElevar won its first FDA approval Sept 23 with Lyrfigtu, a selective FGFR2 inhibitor for advanced cholangiocarcinoma, entering an already-crowded niche third.
September 24, 2026An FDA panel voted 7-2 that GRAIL's Galleri multi-cancer blood test's benefits outweigh its risks, but split 6-4 on effectiveness. A final decision is next.
September 24, 2026 · diagnostics · $GRALKyverna's CD19 CAR-T miv-cel held up at one year in stiff person syndrome, with a rolling BLA due Q4 2026. It could be the first CAR-T for autoimmune disease.
September 24, 2026FDA cleared Lilly's Onswik (insulin efsitora alfa-gobe) Sept 24 for type 2 diabetes, six months after Novo Nordisk's Awiqli opened the once-weekly basal insulin category.
September 24, 2026 · Cardiometabolic · $LLYNovo's CagriSema beat tirzepatide 5 mg on weight loss (12.4% vs 9.1%) in Phase 3, but the rival was dosed at its lowest marketed strength. The caveat matters.
September 24, 2026 · obesity · $NVOScholar Rock won FDA approval Sept 11 for ISEMBYLD, the first muscle-targeted SMA therapy, a myostatin inhibitor layered on top of existing SMN2 drugs.
September 24, 2026Ultragenyx won the first Sanfilippo type A approval Sept 17 with the AAV9 gene therapy FAYUVI, a one-time dose that earned a rare priority review voucher.
September 24, 2026The FDA granted accelerated approval to Bayer's sevabertinib (Hyrnuo) for first-line HER2-mutant NSCLC, the first HER2-directed therapy in the front-line setting. ORR hit 75% in SOHO-01.
September 10, 2026 · Oncology · $BAYRYThe FDA places a partial clinical hold on Biohaven's Kv7 epilepsy drug BHV-7000, pausing new enrollment in RISE 2 and RISE 3 over a rodent metabolite finding.
September 10, 2026 · Neuroscience · $BHVNNovo Nordisk halted HERMES and ATHENA, Phase 3 ziltivekimab trials, after a DSMB found futility. The ARTEMIS post-heart attack trial is the program's last shot.
September 10, 2026The FDA granted Priority Review to Enspryng for MOGAD, a rare CNS autoimmune disease with no approved treatments. PDUFA date is set for January 10, 2027.
September 10, 2026Tyra's SURF302 study of oral dabogratinib in bladder cancer showed 57% 3-month CR at 60 mg, missing the 70% bar, but single-lesion patients hit 100% ORR.
September 10, 2026Imdelltra plus Imfinzi met overall survival in Phase 3 DeLLphi-305 first-line maintenance SCLC — the first BiTE OS win in that setting.
September 9, 2026 · Oncology · $AMGNFDA granted accelerated approval to Etcamah (camizestrant) plus a CDK4/6 inhibitor — the first ctDNA-guided switch therapy in breast cancer.
September 9, 2026 · Oncology · $AZNBridgeBio filed its NDA for oral infigratinib in achondroplasia and showed the FGFR3 inhibitor improves sleep apnea and ear infections, not just height.
September 9, 2026BioMarin's Voxzogo hit its primary endpoint in the first hypochondroplasia Phase 3, improving growth velocity 2.33 cm/yr vs placebo, with filings due H2 2026.
September 9, 2026Bristol Myers Squibb's arlo-cel, a GPRC5D CAR-T, met its primary endpoint in the registrational QUINTESSENTIAL myeloma trial but withheld the response rate.
September 9, 2026The FDA accepted Intellia's lonvo-z for hereditary angioedema with Priority Review and a March 10, 2027 PDUFA date, advancing the first in vivo CRISPR therapy.
September 9, 2026Novartis' del-desiran missed the vHOT endpoint in HARBOR — the second late-stage miss in five days and a setback for the $12B Avidity deal.
September 9, 2026 · Neuromuscular · $NVSPelacarsen cut Lp(a) up to 80% but failed to reduce cardiovascular events in Lp(a)HORIZON — raising the bar for Lilly and Amgen rivals.
September 9, 2026 · Cardiovascular · $NVSAbbVie's etentamig hit 74% ORR and cut progression risk 60% (HR 0.40) in Phase 3 CERVINO for triple-class exposed relapsed/refractory myeloma.
September 3, 2026 · Oncology · $ABBVFDA approved Zanvastro for Alexander disease — the first treatment for the fatal GFAP-driven disorder. Ionis banked a rare-disease PRV.
September 3, 2026 · Neurology · $IONSPfizer licenses its shelved Seagen ADC PF-08046031 to Medicus Pharma for $12M upfront plus up to $1B in milestones; MDCX fell 34% on the dilution risk.
September 3, 2026Apazunersen missed its primary cognition endpoint in Angelman syndrome, erasing nearly half of Ultragenyx's market value overnight.
September 3, 2026 · Rare Disease · $RAREAkeso's HARMONi-2 hit overall survival at interim, making ivonescimab dual-positive on PFS and OS versus Keytruda. Summit surged.
September 3, 2026 · Oncology · $SMMTTagrisso plus Orpathys beat Tagrisso alone on progression-free survival in China's 326-patient SANOVO trial for MET-overexpressing EGFR-mutant lung cancer.
September 2, 2026uniQure submitted its AMT-130 BLA for Huntington's disease, the first gene therapy filing for the disorder. QURE fell 4.7% to $46.23; priority review requested.
September 2, 2026Roche licensed preclinical tri-specific SIM0660 from Simcere Zaiming for $75 million upfront and up to $1.53 billion in milestones, plus tiered royalties.
September 2, 2026Stoke and Biogen reported 4-year durability for zorevunersen in Dravet syndrome, with new sub-analyses on the severe seizures that drive SUDEP deaths.
September 2, 2026Teva's anti-IL-15 antibody TEV-408 met its Phase 2a primary endpoint in celiac disease, cutting gluten-induced gut damage at week 8. TEVA rose to $37.49.
September 2, 2026The FDA accepted United Therapeutics' sNDA for inhaled Tyvaso in IPF, a fatal lung disease. UTHR closed at $492.02, decision expected in late April 2027.
September 2, 2026BridgeBio 42-month CMR data shows acoramidis may reverse cardiac damage in ATTR-CM, with 54% improving LV function vs 20% on placebo. Published in EJHF.
September 1, 2026Novartis halted eight rap-cel trials after three autoimmune patients died from a severe immune response; BMS paused its CAR-T programs too.
September 1, 2026 · Cell Therapy · $NVSNovartis' remibrutinib beat teriflunomide on relapse rate in two Phase 3 MS trials — the first BTK inhibitor with Phase 3 wins, clean liver.
September 1, 2026 · neuroscience · $NVSPlozasiran cut pancreatitis 78% and triglycerides 79-81% in full SHASTA-3/4 data, pressing Tryngolza on safety and quarterly dosing before a year-end sNDA.
August 31, 2026 · $ARWRThe FDA approved PharmaEssentia's BESREMi for essential thrombocythemia, first new ET drug in nearly three decades. SURPASS-ET: 42.9% vs 6.0% anagrelide.
August 31, 2026The FDA approved J&J's Stelara (ustekinumab) for pediatric ulcerative colitis Aug 28, making it the first non-TNF biologic across both pediatric IBD forms.
August 31, 2026Karyopharm submitted an sNDA for selinexor plus ruxolitinib in myelofibrosis, requesting Priority Review under accelerated approval. FDA decision in Q4.
August 31, 2026 · $KPTILilly will acquire Merida Biosciences for up to $2.875B, adding MER511, a Phase 1 autoantibody-degradation therapy for Graves' disease.
August 31, 2026 · Immunology · $LLYHERIZON-GEA-01's second interim met the overall survival co-primary endpoint for Ziihera plus chemo in first-line HER2+ GEA.
August 31, 2026 · oncology · $JAZZThe FDA accepted Nicox's NCX 470, a nitric oxide-donating bimatoprost eye drop for glaucoma, and set an April 30, 2027 PDUFA date. Kowa is the U.S. licensee.
August 30, 2026Teva is the stalking-horse bidder for BioXcel's BXCL501, an at-home agitation film with a Nov. 14 PDUFA date. The $57.5M upfront rides on timing milestones.
August 30, 2026BioXcel Therapeutics filed Chapter 11 and named Teva stalking-horse bidder at $57.5M upfront plus $67.5M in milestones for BXCL501, ahead of the Nov 14 PDUFA.
August 29, 2026BioNTech is ending its Phase 2 autogene cevumeran trial in resected colorectal cancer after a data board flagged a survival imbalance between the two arms.
August 28, 2026Cytokinetics presented full ACACIA-HCM data at ESC 2026, the first positive Phase 3 result in non-obstructive HCM, with an sNDA filing planned for Q4.
August 28, 2026The FDA cleared Mounjaro to lower heart attack, stroke, and cardiovascular death risk in adults with type 2 diabetes, a first for any GIP/GLP-1 drug ever.
August 28, 2026 · Cardiometabolic · $LLYFDA approved MIMRYLO (rusfertide) for erythrocytosis in polycythemia vera — the first hepcidin mimetic; VERIFY hit 76.9% vs 32.9%.
August 28, 2026 · Hematology · $PTGXTezspire met both co-primary endpoints in Phase 3 CROSSING for eosinophilic esophagitis, targeting a third epithelial indication.
August 27, 2026 · immunology · $AMGNGilead's Bixlenvo won FDA approval Aug 27 as the first single-tablet regimen for suppressed adults on complex HIV regimens.
August 27, 2026 · Infectious disease / HIV · $GILDRoivant's LISRAYA (brepocitinib) is the first targeted therapy approved for dermatomyositis, clearing the FDA five weeks ahead of PDUFA.
August 27, 2026 · Immunology · $ROIVBiohaven licenses its Kv7 epilepsy platform and lead drug opakalim to SK Biopharmaceuticals, which funds development toward a 2029 launch, for up to $795M.
August 26, 2026Celcuity filed an sNDA to extend REVTORPYK (gedatolisib) to PIK3CA-mutant breast cancer after beating Novartis' Piqray in the VIKTORIA-1 mutant cohort.
August 26, 2026Fulcrum reverse-merges with migraine biotech Slate Medicines in an all-stock deal backed by a $245M PIPE, with the combined company set to trade as SLTE.
August 26, 2026FDA approved ViiV's Tivicay PD for newborns from birth — dolutegravir is the first integrase inhibitor cleared for this population.
August 26, 2026 · Infectious Disease · $GSKRoche's Genentech licensed Hanmi's HM17321, a urocortin-2 analog that preserves lean muscle mass, for $190M upfront and up to $2.3B in milestone payments.
August 26, 2026Revolution Medicines' daraxonrasib won FDA approval in metastatic pancreatic cancer after nearly doubling median OS to 13.2 months.
August 26, 2026Ivonescimab beat Imfinzi on overall survival in first-line biliary tract cancer in the China-only HARMONi-GI1 trial, its fifth positive Phase 3 readout.
August 26, 2026Spyre's anti-TL1A antibody SPY072 hit its RA primary endpoint but missed the efficacy bar, so the company is pivoting to psoriasis and ulcerative colitis.
August 26, 2026FDA accepted GSK's Jemperli sBLA for stage II/III dMMR rectal cancer with Priority Review — a shot at the first organ-preservation label.
August 25, 2026Two Ziihera regimens cleared first-line HER2+ gastroesophageal adenocarcinoma with 26.4-month median OS — longest ever in the setting.
August 25, 2026 · oncology · $JAZZFDA approved J&J's IMAAVY (nipocalimab) as the first therapy for warm autoimmune hemolytic anemia; ~3x durable response rate vs placebo.
August 25, 2026 · Immunology · $JNJIntismeran met RFS and DMFS endpoints in INTerpath-001 — the first Phase 3 win for a personalized mRNA cancer vaccine. MRNA doubled.
August 25, 2026FDA put REGENXBIO's RGX-121 on clinical hold after spine MRI findings; the Hunter syndrome gene therapy won't be resubmitted. RGNX fell 25%.
August 25, 2026 · Gene Therapy · $RGNXSkye Bioscience reverse-merges with Redx Pharma to form Fibrx Therapeutics, a $125M-backed fibrosis company led by RXC008 in fibrostenotic Crohn's disease.
August 25, 2026The FDA accepted United Therapeutics' ralinepag NDA for PAH, setting a June 24, 2027 decision. It would be the first once-daily oral prostacyclin for adults.
August 25, 2026Activist Kaos Capital seeks Capricor (CAPR) board changes and an M&A review days before the deramiocel PDUFA. Shares have lost two-thirds since late July.
August 22, 2026The FDA issued a CRL for ITM 177Lu-edotreotide in GEP-NETs on Aug 7, citing only manufacturing and facility items. The Phase 3 COMPETE win still stands.
August 22, 2026Seven deaths and 100+ serious adverse events for Neurocrine Vykat XR in Prader-Willi have surfaced in FDA post-marketing data. NBIX stands by the drug.
August 22, 2026Vogenx (VOGX) priced an $81M IPO at $13 and ran to $29.52 as mizagliflozin, an oral SGLT1 inhibitor for post-bariatric hypoglycemia, rode the Amylyx wave.
August 22, 2026Amylyx's avexitide cut Level 2/3 hypoglycemia 55% in Phase 3 LUCIDITY for post-bariatric hypoglycemia — no approved rival therapy exists.
August 21, 2026 · Metabolic · $AMLXargenx's ALKIVIA Phase 3 hit its primary endpoint: efgartigimod beat placebo by 15.4 points on Total Improvement Score in myositis.
August 21, 2026 · Immunology · $ARGXEnhertu met its primary endpoint in DESTINY-Lung04 — first HER2-directed drug to beat standard of care in first-line HER2-mutant NSCLC.
August 21, 2026 · Oncology · $AZNBioMarin (BMRN) buys Alesta for $275M upfront, adding ALE1, a Phase 1/2a oral drug for hypophosphatasia that could rival AstraZeneca's injectable Strensiq.
August 21, 2026The FDA approved Bristol Myers Squibb's Zenbexus (iberdomide) for relapsed multiple myeloma, the first CELMoD. MRD-negative response hit 41% versus 21%.
August 21, 2026 · Oncology · $BMYCapricor (CAPR) will amend its deramiocel BLA to an upper-limb-only claim after the 9-3 AdCom vote, pushing the Aug 22 PDUFA back. The FDA may still reject it.
August 21, 2026Werewolf (HOWL) reverse-merges with Ambros, which gets 71.7% plus a $150M PIPE to fund neridronate for CRPS-1. It will re-trade on Nasdaq as AMBX next year.
August 21, 2026Moderna and Merck's personalized cancer vaccine met its INTerpath-001 primary endpoint, cutting melanoma recurrence; MRNA closed up 177%.
August 21, 2026 · Oncology · $MRNAThe FDA approved Ultragenyx's Genglycos (DTX401), the first gene therapy for GSDIa. It cuts daily cornstarch needs and earned a priority review voucher.
August 21, 2026 · Rare Disease · $RAREThe FDA approved Regeneron's Pasatru (garetosmab) for FOP, a disorder where bone grows in muscle. It cut new bone lesions 90% in OPTIMA and reduced flare-ups.
August 21, 2026 · Rare Disease · $REGNSionna's SION-719 missed its sweat chloride target in a 15-patient Phase 2a CF trial with -1.0 mmol/L, far below the 5-7 mmol/L bar. VRTX rose 6% to $524.
August 11, 2026AbCellera's NK3R antibody cut moderate-to-severe hot flashes by 83% at week 4 with a single 600 mg dose. At $9.34, the stock added roughly $550M in market cap.
August 10, 2026Sobi pays Innate $75M upfront for lacutamab, a first-in-class antibody for Sézary syndrome. The deal funds the Phase 3 trial toward accelerated approval.
August 10, 2026Jazz will pay $820M upfront plus $500M milestones for Actio's KCNT1 inhibitor, aimed at a rare epilepsy with no approved therapies.
August 10, 2026 · CNS · $JAZZJazz will withdraw Zepzelca's second-line SCLC approval after LAGOON failed. Two confirmatory misses in six years close the accelerated approval chapter.
August 10, 2026Sonelokimab hit 42.1% ACR50 at Week 16 in biologic-naive psoriatic arthritis; the IL-17A/F Nanobody now has Phase 3 wins in two markets.
August 10, 2026 · rheumatology · $MLTXRevolution Medicines licensed Asian rights to four RAS(ON) inhibitors to BeOne, which funds a global Phase 3 trial. RVMD retains US, Europe, Japan, Korea.
August 10, 2026Silence Therapeutics' divesiran produced an 88% response rate vs 19% placebo in the Phase 2 SANRECO trial of phlebotomy-dependent PV. SLN jumped 42% intraday.
August 10, 2026Tenax's TNX-103 missed the 6-minute walk endpoint in the Phase 3 LEVEL trial for PH-HFpEF, a non-significant 3.5m gap vs placebo. TENX fell roughly 90% intraday.
August 10, 2026 · cardiovascular · $TENXIovance posted Q2 revenue of $99.3M, up 66%, on record Amtagvi sales. The TIL therapy for melanoma hit 56% gross margin and the stock surged 43% on the beat.
August 9, 2026Otsuka VOYXACT delivered the largest eGFR treatment effect ever in an IgAN Phase 3 trial. The APRIL inhibitor showed +0.3 slope vs -4.2 for placebo at GlomCon.
August 9, 2026Arcturus (ARCT) terminated its $4.3B CSL vaccine deal, regaining KOSTAIVE rights. ARCT-032 inhaled mRNA for cystic fibrosis is now the investment thesis.
August 8, 2026BioVie stock dropped 50% after the bezisterim Phase 2 SUNRISE-PD readout in early PD. The primary endpoint was buried behind a self-constructed composite scale.
August 8, 2026BlossomHill Therapeutics priced an upsized $150M IPO at $16 for two oncology programs: BH-30643 in EGFR NSCLC and BH-30236 in AML. Shares trade as BLSM.
August 7, 2026BioMarin discontinued BMN 401 across all indications on August 6, writing off the $270M Inozyme deal. VOXZOGO raised 2026 guidance to at least $1 billion.
August 7, 2026Merck and Gilead ended the KEYNOTE-D46/EVOKE-03 trial after the E-DMC said Trodelvy plus Keytruda would not beat Keytruda alone on OS in first-line PD-L1+ NSCLC.
August 7, 2026Latigo Biotherapeutics priced a $345.6M IPO at $18 for LTG-001, an oral Nav1.8 inhibitor with positive Phase 2 data. Shares trade today as LTGO on Nasdaq.
August 7, 2026Sanofi suspended SAR445399 in NCFB, the fourth pipeline program cut under new CEO Belén Garijo. The trial was halted July 29 for strategic reasons, not safety.
August 7, 2026A senior source denied any AstraZeneca-Bristol merger talks on Aug 5, three days after the FT reported preliminary discussions. AZN shares recovered 6%.
August 6, 2026 · Pharma · $AZN, BMYBraveheart Bio (BRVE) surged 66% to $29.80 on Nasdaq debut after a $382.5M IPO to fund Phase 3 trials of BHB-1893, a Hengrui-licensed cardiac myosin inhibitor.
August 6, 2026 · Cardiometabolic · $BRVEThe FDA accepted Merck ENFLONSIA sBLA to expand RSV protection to high-risk children under 2. SMART trial showed antibody levels comparable to healthy infants.
August 6, 2026The FDA approved Moderna mFLUVISA on Aug 5, the first mRNA seasonal flu vaccine in the US. Phase 3 showed 26.6% higher efficacy vs standard-dose flu shots.
August 6, 2026 · Vaccines · $MRNAFDA approved Replimune's Tudriqev (RP1) plus nivolumab for anti-PD-1-resistant melanoma — the first oncolytic virus approval in melanoma.
August 6, 2026 · Oncology · $REPLSummit (SMMT) launched HARMONi-GU1, a Phase 2/3 trial of ivonescimab-Padcev in bladder cancer, its 16th registrational study ahead of the Nov 14 NSCLC PDUFA.
August 6, 2026Tarsus (TARS) will acquire Alkeus for $450M upfront, adding Phase 3 gildeuretinol for Stargardt disease, a rare retinal disorder with no FDA-approved treatment.
August 6, 2026 · Ophthalmology · $TARSGilead Q2 revenue grew 10% to $7.8B driven by HIV, but GAAP EPS swung to $(8.45) on $9.08/share in acquisition charges. Base business is healthy. Here is what matters.
August 5, 2026 · Infectious Disease · $GILDEli Lilly Q2 revenue jumped 48% to $23B on Mounjaro and Zepbound. Retatrutide Phase 3 is complete with a BLA filing planned for Q1 2027. Here is what matters.
August 5, 2026 · Cardiometabolic · $LLYMerck Q2 revenue hit $16.6B but a $5.7B Terns acquisition charge produced a $(0.54) GAAP loss. Full-year EPS guidance was cut to $2.66-$2.76 from $5.04-$5.16.
August 5, 2026Novo Nordisk Q2 sales hit DKK78.5B on semaglutide strength, but a DKK4B monlunabant write-down clouds the post-Wegovy pipeline. Here is what matters now.
August 5, 2026Novo Nordisk took DKK 6.3B in pipeline impairments including DKK 4B for monlunabant. Core GLP-1 franchise strong but beyond-GLP-1 pipeline is thinning fast.
August 5, 2026 · Cardiometabolic · $NVOPfizer beat Q2 estimates (EPS $0.77 vs $0.68) and raised guidance, but axed two obesity programs from its $10B Metsera pipeline. Only berobenatide remains.
August 5, 2026Pfizer beat Q2 estimates (EPS $0.77 vs $0.68) but axed MET-224o and a GIPR candidate from its $10B Metsera acquisition. Only berobenatide remains as the obesity bet.
August 5, 2026 · Cardiometabolic · $PFEThe IL-31-focused biotech raised 45% more than originally planned, pricing 17 million shares at $17.00 ahead of its Nasdaq debut under ticker ATTO.
August 4, 2026 · Immunology · $ATTORhythm RM-718 showed -11.6% BMI in hypothalamic obesity across 7 patients at 16 weeks. The MC1R-sparing agonist targets better tolerability than setmelanotide.
August 4, 2026Curium will buy Lantheus for up to $114.50/share ($102.50 cash plus $12 CVR) — up to $8B, the largest radiopharma deal yet.
August 3, 2026 · Radiopharma / M&A · $LNTHSupernus and Indivior will merge in an all-stock deal of equals: $2.2B revenue, 11 approved CNS drugs, $125M in cost synergies.
August 3, 2026 · CNS / M&A · $SUPNVertex (VRTX) posted $3.33B in Q2 2026 revenue, raised guidance, and got a Nov. 30 PDUFA for povetacicept in IgA nephropathy. The first non-CF pillar is near.
August 3, 2026AstraZeneca held months of merger talks with Bristol Myers Squibb worth nearly $400B, the FT reported — the largest pharma deal ever floated.
August 2, 2026 · M&A · $AZNOtsuka's VOYXACT became the first APRIL inhibitor to show 2-year eGFR stabilization in IgAN. The data supports its rolling sBLA for traditional FDA approval.
August 2, 2026Selinexor missed PFS in XPORT-EC-042 endometrial cancer with HR 0.76 and CI crossing 1.0. Karyopharm now hinges on its August myelofibrosis sNDA filing.
August 1, 2026Karyopharm filed its selinexor plus ruxolitinib sNDA in myelofibrosis Aug 31, seeking accelerated approval; FDA decision possible H1 2027.
August 1, 2026BMY pushed Cobenfy ADEPT and milvexian LIBREXIA-AF readouts to 2027. Slower enrollment resets the catalyst calendar. The iberdomide PDUFA on August 17 is next.
July 31, 2026Moderna's mRNA-1403 norovirus vaccine missed early-success criteria at a Phase 3 interim; shares fell 5.4% as a new cohort enrolls.
July 31, 2026 · mRNA · $MRNANovo's ziltivekimab missed ZEUS with a MACE hazard ratio of 0.99; the IL-6 cardio thesis now needs HERMES and ARTEMIS to survive.
July 31, 2026 · biotech · $NVOFDA approved Pluvicto in PSMA+ metastatic hormone-sensitive prostate cancer 13 days early — roughly a fourfold larger patient population.
July 31, 2026 · Oncology / Radiopharmaceuticals · $NVSThe FDA accepted Saol SL1009 resubmission for PDCD with a Dec. 30 PDUFA. No approved therapies exist. A Priority Review Voucher worth $100M+ is on the table.
July 31, 2026Agios Q2: FDA granted Priority Review for the mitapivat sickle cell sNDA with a Nov 1 PDUFA. Cevidoplenib licensed and AG-236 siRNA advances to Phase 2/3.
July 30, 2026Alnylam Q2: Net product revenue hit $1.17B as AMVUTTRA crossed $1B for the first time. A TTR guidance cut to $4.2-$4.5B sent shares down 29% on July 30.
July 30, 2026Apnimed (APMD) upsized its IPO to 12M shares at $16, raising $192M for AD109, the first oral pill for obstructive sleep apnea.
July 30, 2026 · Sleep medicine / neuroscience · $APMDIonis posted Q2 revenue of $268M with a $115M net loss. Salanersen earned FDA Breakthrough Therapy for annual-dose SMA. Two FDA decisions are due by October.
July 30, 2026JNJ Rybrevant Faspro sBLA for head and neck cancer got FDA Priority Review. OrigAMI-4 showed 42% ORR with 15% complete responses. PDUFA expected in Q1 2027.
July 30, 2026J&J will pay $785M upfront and hold a $2.58B acquisition option on Sail Biomedicines' in vivo CAR-T platform for autoimmune disease.
July 30, 2026 · Cell Therapy · $JNJPfizer's LITFULO met co-primary endpoints in two Phase 3 vitiligo trials — arriving second to a market AbbVie's Rinvoq just opened.
July 30, 2026 · dermatology · $PFEFDA advisors voted 10-3 that RP1 plus nivolumab has favorable benefit-risk in anti-PD-1-resistant melanoma; REPL jumped 39% after hours.
July 30, 2026 · oncology · $REPLAstraZeneca's Ultomiris missed its primary endpoint in HSCT-TMA — the second Alexion Phase 3 failure in July after eplontersen.
July 29, 2026 · Rare Disease / Hematology · $AZNBiogen Q2 2026: Growth Portfolio hit $1.06B, overtaking Legacy MS revenue for the first time. Leqembi reached $184M. Five registrational readouts ahead.
July 29, 2026FDA advisors voted 9-3 that Capricor's HOPE-3 failed to show substantial evidence for deramiocel in DMD — the Aug 22 PDUFA leans rejection.
July 29, 2026 · cell-therapy · $CAPRCabenuva cut viral rebound 7x vs daily pills in LATA adolescent HIV trial. GSK ViiV also showed OPERA real-world data and EXTEND 4M PrEP at AIDS 2026.
July 29, 2026 · infectious-disease · $GSKViiV 2-drug Dovato matched Gilead 3-drug Biktarvy in VOGUE at 89% vs 92% suppression. First head-to-head HIV data could shift first-line prescribing patterns.
July 29, 2026 · infectious-disease · $GSKOak Hill Bio raises $175M via RA Capital SPAC to advance rugonersen toward Phase 3 for Angelman syndrome. No FDA-approved treatments exist for the disorder.
July 29, 2026 · rare-disease · $OAKHFDA cleared Viatris Gwyn Lo on July 29, a day before PDUFA. The low-estrogen weekly patch is restricted to women with BMI below 30 and launches later in 2026.
July 29, 2026ALT pemvidutide reduced heavy drinking and cut blood alcohol biomarker 38% in RECLAIM Phase 2. The GLP-1 class just entered addiction medicine. Here is why.
July 28, 2026Atea HCV pill matched Epclusa in C-BEYOND Phase 3: 93.9% vs 94.8% SVR, shorter 8-week course in most patients. Market shrugged. AVIR at $4.82. Here is why.
July 28, 2026Axsome AXS-12 (reboxetine) for cataplexy in narcolepsy gets a May 1 2027 PDUFA. Two Phase 3 trials met endpoints. First cataplexy-specific therapy if approved.
July 28, 2026FDA accepted Cullinan/Taiho's NDA for zipalertinib in EGFR exon 20 insertion NSCLC. PDUFA is Feb 27, 2027, with 40% ORR in chemo-pre-treated patients.
July 28, 2026The FDA accepted Cogent bezuclastinib plus sunitinib NDA in GIST with PDUFA November 30. PEAK trial PFS was 16.5 vs 9.2 months, first win in 20 years.
July 28, 2026GSK beat Q2 with £8.41B revenue and launched a £1.9B cost-savings program to fund 20+ Phase III trial starts in 2026. Bepirovirsen PDUFA is October 26.
July 28, 2026GSK licensor Hansoh reported positive ARTEMIS-011 Phase 3 in relapsed osteosarcoma on July 28. It is the second Phase 3 win for the B7-H3 ADC after SCLC.
July 28, 2026FDA accepted Immunome NDA for varegacestat in desmoid tumors with April 28, 2027 PDUFA. RINGSIDE showed 84% risk reduction and 56% ORR. IMNM at $22.58.
July 28, 2026LEGN CEO Ying Huang stepped down July 24 with no permanent successor. CARVYKTI hit $657M in Q2 as J&J bispecific combo poses a new threat to the franchise.
July 28, 2026MapLight ML-007 met the primary PANSS endpoint in ZEPHYR but once-daily dosing failed. MPLT crashed 73% Monday, rebounded to $12.31 as the BID dose held.
July 28, 2026FDA briefing docs called Replimune's RP1 data 'not interpretable' — then advisors voted 10-3 to back it and the FDA approved Aug 6.
July 28, 2026 · oncology · $REPLSarepta appointed Michael Severino, the former AbbVie R&D chief who built Rinvoq and Skyrizi, as CEO effective July 28. SRPT is down 91% from its 2024 high.
July 28, 2026Argenx will buy Forte Biosciences for $77/share cash (~$2.2B), adding anti-CD122 antibody FB102 on vitiligo and celiac proof-of-concept data.
July 27, 2026 · immunology · $ARGXArrowhead completed YOSEMITE enrollment for zodasiran in HoFH. 70 patients enrolled, topping the 60-patient target. Study completion expected mid-2027.
July 27, 2026AstraZeneca's sonesitatug vedotin hit overall survival in CLARITY-Gastric01 in CLDN18.2+ gastric cancer, with a broader test threshold.
July 27, 2026 · oncology · $AZNFDA briefing docs say Capricor's HOPE-3 missed its primary endpoint, citing post-hoc changes; CAPR fell 65% before the AdComm vote.
July 27, 2026 · cell-therapy · $CAPRThe FDA accepted Organogenesis's BLA for ReNu in knee OA with an April 24, 2027 PDUFA. It would be the first biologic for 31 million knee OA patients.
July 27, 2026The FDA accepted Pharvaris's NDA for deucrictibant IR in hereditary angioedema with an April 23, 2027 PDUFA. It would be the first oral on-demand HAE therapy.
July 27, 2026The FDA extended Beren Therapeutics' PDUFA for adrabetadex in infantile-onset Niemann-Pick type C to November 17, 2026. A major amendment triggered the delay.
July 26, 2026Lirafugratinib was approved September 23 as Lyrfigtu for FGFR2-driven cholangiocarcinoma — Elevar's first US approval, four days ahead of its Sept 27 PDUFA.
July 26, 2026INOVIO's INO-3107 DNA medicine for recurrent respiratory papillomatosis faces an October 30 PDUFA. The FDA questioned the accelerated approval pathway.
July 26, 2026ONO's tirabrutinib NDA for relapsed CNS lymphoma has a December 18 PDUFA. PROSPECT showed 67% ORR and 44% CR. No approved therapy exists for R/R PCNSL.
July 26, 2026Vanda's imsidolimab BLA for GPP has a December 12 PDUFA. GEMINI showed 53% clear skin vs 13% placebo and zero flares. Spevigo owns the two-drug market.
July 26, 2026Zydus Lifesciences' saroglitazar for PBC has a November 27 PDUFA date. Phase 3 showed 56.7% response vs 9.8% placebo. No US ticker; trades on Indian NSE.
July 26, 2026ACADIA won FDA Fast Track for remlifanserin in Alzheimer's disease psychosis, a condition with no approved therapies. RADIANT Phase 2 data read out as a near-miss on September 25.
July 25, 2026CHMP backed Enhertu plus pertuzumab as first-line HER2 metastatic breast cancer. DESTINY-Breast09 showed 40.7 vs 26.9 months median PFS. AZN closed at $169.26.
July 25, 2026EU approved AstraZeneca's Etcamah for ESR1-mutant breast cancer on SERENA-6; the FDA granted accelerated US approval in September.
July 25, 2026FDA approved LEQEMBI IQLIK subcutaneous initiation dosing July 13 — the first anti-amyloid therapy with at-home dosing from day one.
July 25, 2026FDA issued a third CRL for Elevar's rivoceranib in liver cancer. The 23.8-month OS was never the problem. Manufacturing failures killed an approvable drug.
July 25, 2026GSK discontinued camlipixant after CALM-2 failed, writing off the $2B Bellus Health buyout. The P2X3 class is now dead for chronic cough; Trevi rose 12%.
July 25, 2026The EMA's CHMP recommended GSK's Lynavoy (linerixibat), the first IBAT inhibitor for cholestatic pruritus in PBC, setting up EU approval within 67 days.
July 25, 2026Ipsen Phase 3 BOLD trial of Bylvay in biliary atresia missed its primary endpoint. The first global Phase 3 in the disease came up empty for IPSEY holders.
July 25, 2026The EMA's CHMP backed J&J's Icotyde (icotrokinra), the first oral IL-23 receptor antagonist, for moderate-to-severe plaque psoriasis in adults and teens 12+.
July 25, 2026FDA granted De Novo authorization for JNJ's OTTAVA robotic surgery system. First table-integrated robot challenges ISRG da Vinci monopoly. JNJ at $263.40.
July 25, 2026Lilly will acquire AtaiBeckley for $2.8B upfront plus $1B in CVRs, adding BPL-003 for treatment-resistant depression. Largest psychedelic deal to date.
July 25, 2026Merck announced access plans for alimatravir on July 24. The monthly oral HIV PrEP pill is in Phase 3. Seven generic licenses span 129 LMIC countries.
July 25, 2026Kelun sac-TMT plus Keytruda beat chemo plus Keytruda in first-line PD-L1-negative NSCLC. First Phase 3 win for an ADC-ICI combination gives Merck a blueprint.
July 25, 2026Novo sued Eli Lilly on July 21 over ads claiming Zepbound beats Wegovy. The complaint cites outdated trial data comparing Lilly's top dose to Novo's lower dose.
July 25, 2026REGENXBIO dosed the first patient in the NAAVIGATE trial of sura-vec gene therapy for diabetic retinopathy, unlocking a $100M AbbVie milestone payment.
July 25, 2026Roche discontinued acmopatide to prioritize enicepatide, which showed 22.5% weight loss with no plateau at 48 weeks. Carmot bet narrows to one obesity asset.
July 25, 2026The EMA's CHMP recommended Roche's Susvimo for wet AMD on July 24. The refillable eye implant cuts injections to twice a year. Already FDA-approved in the US.
July 25, 2026The EMA's CHMP backed Shionogi's Zokovea (ensitrelvir), the first oral antiviral for COVID-19 post-exposure prophylaxis, with EU approval expected in 67 days.
July 25, 2026Sanofi dropped amlitelimab in eczema on July 24, 2026 after Phase 3 data failed to clear the filing bar. Second OX40L drug shelved. SNY closed at $43.35.
July 25, 2026The FDA has a July 30 PDUFA date for Viatris Xulane LO, a weekly contraceptive patch cutting estrogen to 17.5 mcg from 35 mcg. VTRS closed at $17.24 on July 24.
July 25, 2026EMA CHMP rejected Zevra Miplyffa in Niemann-Pick disease type C. FDA approved the same drug in September 2024. Zevra seeks re-examination of the decision.
July 25, 2026Agios discontinued tebapivat in SCD after Phase 2 showed limited differentiation. Mitapivat sNDA has Nov 1 PDUFA. Novo Nordisk etavopivat gains ground.
July 24, 2026Agios discontinued tebapivat in sickle cell after Phase 2 showed no differentiation. Mitapivat Phase 3 RISE UP is the remaining SCD catalyst. AGIO at $36.28.
July 24, 2026FDA proposed withdrawing TAVNEOS after ADVOCATE data manipulation; Amgen submitted new data July 23 requesting a hearing.
July 24, 2026 · Immunology / Rare Disease · $AMGNArrowhead's plozasiran delivered 79-81% triglyceride cuts and zero pancreatitis events in the highest-risk subgroup of SHASTA-3/4.
July 24, 2026 · Cardiometabolic · $ARWRBridgeBio's encaleret NDA for ADH1, an ultra-rare calcium disorder with no approved treatments, was accepted by the FDA with a PDUFA date of May 8, 2027.
July 24, 2026The FDA's CTGTAC meets July 29 to review Capricor's deramiocel for DMD cardiomyopathy. A rescinded CRL and $1.1B market cap make this a binary catalyst.
July 24, 2026Celldex discontinued barzolvolimab in prurigo nodularis after a Phase 2 miss despite profound mast cell depletion, putting the Q4 AD readout in question.
July 24, 2026FDA approved Keytruda plus Padcev for muscle-invasive bladder cancer. KEYNOTE-B15 showed 47% EFS and 35% OS risk reductions versus chemotherapy in 808 patients.
July 24, 2026 · Oncology · $MRKEMA CHMP backed Trodelvy plus Keytruda in PD-L1+ first-line metastatic TNBC, based on a 35% risk reduction from ASCENT-04. GILD closed at $130.86 on July 23.
July 24, 2026Ionis and AstraZeneca eplontersen missed Phase 3 in ATTR cardiomyopathy. The largest ATTR-CM trial failed on background TTR stabilizers. IONS closed at $56.55.
July 24, 2026J&J's TECVAYLI plus TALVEY cut progression or death risk 89% (HR 0.11) in MonumenTAL-6 — lowest HR in any bispecific myeloma trial.
July 24, 2026 · Oncology · $JNJFDA approved MNKD FUROSCIX ReadyFlow on July 24, two days ahead of PDUFA. It delivers IV-equivalent furosemide in under 10 seconds for heart failure and CKD.
July 24, 2026 · Cardiovascular · $MNKDFDA granted Novartis traditional approval for Fabhalta in IgA nephropathy — a stronger position than Trutakna's or Voyxact's accelerated.
July 24, 2026 · Nephrology · $NVSThe FDA has a July 29 PDUFA for Novo Nordisk's denecimig (Mim8) for subcutaneous prophylaxis in hemophilia A. Flexible dosing could challenge Roche's Hemlibra.
July 24, 2026FDA approved Lytenava for wet AMD on July 24, five days early. First approved ophthalmic bevacizumab after three prior CRLs. OTLK at $1.32, cap $247M.
July 24, 2026 · Ophthalmology · $OTLKFDA approved Otsuka's SIMTRIYO (centanafadine) — the first norepinephrine-dopamine-serotonin reuptake inhibitor for ADHD, on July 24.
July 24, 2026 · neuroscience · $OTSKYFDA granted accelerated approval to Replimune's Tudriqev (RP1) plus nivolumab for advanced melanoma after two CRLs and a 10-3 AdComm vote.
July 24, 2026 · Oncology · $REPLScribe Therapeutics (SCTX) priced an upsized IPO at $15/share, raising $128.7M for CRISPR cholesterol-lowering genetic medicines.
July 24, 2026 · Cardiometabolic · $SCTXFDA approved Sanofi Sarclisa Escena on-body injector for myeloma. First anticancer drug delivered via wearable device. Infusion reactions dropped 25% to 1.5%.
July 24, 2026Summit reported updated OS data showing a 24% death risk reduction in Western patients with EGFR-mutant lung cancer. The PDUFA date is November 14, 2026.
July 24, 2026FDA granted accelerated approval to Vera Trutakna for IgA nephropathy, first dual BAFF/APRIL inhibitor to reduce proteinuria. A 46% reduction supports approval.
July 24, 2026FDA expanded Vertex Casgevy to ages 2+ on July 1, 2026. First CRISPR therapy for pediatric sickle cell and beta thalassemia, approved in 53 days under CNPV.
July 24, 2026 · Gene therapy · $VRTXFDA approved GSK's Jideytro (zidesamtinib) for treated ROS1+ lung cancer two months early, a week after the Nuvalent acquisition closed.
July 23, 2026 · Oncology · $GSKLilly's retatrutide hit primary endpoints in TRIUMPH-2 and TRIUMPH-3 with up to 22.6% weight loss; a Q1 2027 FDA filing is planned.
July 23, 2026 · Metabolic · $LLYFDA approved Merck's LIPFENDRA, the first oral PCSK9 inhibitor: 56-59% LDL-C cuts in Phase 3 could unlock the stalled PCSK9 market.
July 23, 2026 · Cardiometabolic · $MRKFDA approved Vertex's suzetrigine (Journavx) for acute pain — the first new pain class in 25 years. The chronic pain push is next.
July 21, 2026 · Rare Disease · $VRTX